LILRA4

LILRA4 (ILT7) is a plasmacytoid dendritic cell (pDC)-selective activating receptor that acts as a negative regulator of type I interferon responses (PMID:16735691, PMID:12384430). It lacks intrinsic signaling motifs and instead pairs with the ITAM-bearing adaptor FcεRIγ, an association required for its surface expression; cross-linking of the ILT7–FcεRIγ complex drives phosphorylation of Src-family kinases and Syk, calcium influx, and downstream MEK1/2–ERK–c-FOS signaling that suppresses TLR7/9-induced type I IFN and proinflammatory cytokine production (PMID:16735691, PMID:18048391, PMID:29535732). Syk occupies a pivotal node, since it both promotes TLR-driven IFN-α and transmits the inhibitory ILT7 signal (PMID:27258042). The physiological ligand is BST2 (CD317), which binds purified ILT7 directly and engages it as a stable homodimer through a coiled-coil ectodomain surface, with coiled-coil conformational plasticity required for receptor triggering and the BST2 N-terminal region acting to suppress activation—establishing a structural negative-feedback loop in which IFN- and cytokine-induced BST2 restrains pDC IFN output (PMID:19564354, PMID:31118237, PMID:19723650). This axis is exploited during HIV-1 infection: HIV-1 Vpu relocates BST2 away from viral assembly sites so it remains free to engage and activate ILT7 during cell-to-cell contact, dampening pDC antiviral IFN, a function not efficiently performed by HIV-1 group O Nef (PMID:26172439, PMID:27581991).

1. 2002 Medium

   Establishing that ILT7 is a pDC-restricted gene defined the cell type in which its receptor function would later be interpreted.

   Evidence cDNA subtractive hybridization comparing pDCs to monocyte-derived DCs

   PMID:12384430

   Open questions at the time

   • Expression pattern alone did not address receptor function
   • No ligand or signaling partner identified at this stage
2. 2006 High

   The discovery that ILT7 partners with FcεRIγ and triggers Src/Syk-dependent calcium flux to suppress IFN answered how a receptor with no signaling motif regulates pDCs.

   Evidence Co-IP of the ILT7–FcεRIγ complex, anti-ILT7 cross-linking with kinase inhibitors, calcium flux, and cytokine ELISA in primary pDCs

   PMID:16735691

   Open questions at the time

   • The natural ligand was not yet identified
   • Downstream effectors beyond proximal Src/Syk kinases unresolved
3. 2007 Medium

   Showing that FcεRIγ association is required for ILT7 surface expression and that distinct antibodies have opposing effects clarified the receptor's assembly and dynamic regulation.

   Evidence SAGE screening, surface expression analysis, and functional antibody cross-linking with CpG stimulation in primary pDCs

   PMID:18048391

   Open questions at the time

   • Molecular basis for opposing antibody effects not defined
   • Single-lab functional data
4. 2009 High

   Identifying BST2 as the direct ligand defined a negative-feedback circuit, since BST2 is induced by IFN and cytokines and then activates ILT7 to shut down pDC IFN.

   Evidence ILT7-reporter ligand screen, direct binding with purified ILT7 and BST2, and cytokine inhibition in primary pDCs; complemented by reporter-based detection of BST2 on cancer cells and IFN/cytokine-exposed cells

   PMID:19564354 PMID:19723650

   Open questions at the time

   • Structural basis of BST2–ILT7 binding not yet defined
   • Whether feedback operates on immature versus mature pDCs unresolved
5. 2013 Medium

   Testing BST2 blockade and culture-induced ILT7 loss reframed the BST2-ILT7 axis as a homeostatic control on immature circulating pDCs rather than a feedback brake on activated pDCs.

   Evidence ILT7 cross-linking and BST2 blocking antibodies in primary human PBMCs with TLR7/9 ligands and HIV stimulation, flow cytometry, cytokine measurement

   PMID:23401591

   Open questions at the time

   • BST2 blockade failing to alter IFN-I leaves the in vivo dominance of the axis unclear
   • Single-lab observation
6. 2014 Medium

   Demonstrating that ILT7 engagement reshapes pDC surface markers and preserves T-cell stimulatory capacity established that the receptor biases differentiation toward antigen presentation rather than IFN production.

   Evidence ILT7 cross-linking in PBMC cultures with surface-marker flow cytometry and pDC–T cell co-culture proliferation assays

   PMID:24586760

   Open questions at the time

   • Signaling link between ILT7 and the differentiation phenotype not mapped
   • In vivo relevance untested
7. 2015 High

   Showing that HIV-1 Vpu relocates BST2 to keep it free to activate ILT7 explained how the virus co-opts this inhibitory axis to suppress pDC antiviral IFN.

   Evidence Cell-to-cell contact assays between HIV-producing T cells and pDCs, Vpu mutants, BST2 surface localization imaging, and ILT7 cross-linking functional readout

   PMID:26172439

   Open questions at the time

   • Quantitative contribution of this axis to overall HIV immune evasion not established
8. 2016 Medium

   Defining Syk's dual role and the MEK1/2-ERK-c-FOS axis, together with comparative viral protein analysis, resolved the downstream signaling cascade and showed it is differentially exploited across HIV lineages.

   Evidence Pharmacological Syk inhibition and phosphorylation kinetics in pDCs and GEN2.2 cells; comparative O-Nef versus M-Vpu BST2-relocation and pDC IFN sensing assays

   PMID:27258042 PMID:27581991

   Open questions at the time

   • How Syk discriminates activating TLR versus inhibitory ILT7 signals not resolved
   • Single-lab pharmacological dissection
9. 2018 Medium

   Mapping the inhibitory pathway to a BCR-like MEK1/2-ERK-c-FOS cascade identified the specific effector module through which ILT7 suppresses TLR9-driven IFN.

   Evidence ILT7/BDCA-2 cross-linking with MEK1/2 inhibitors, c-FOS expression/phosphorylation, and IFN-I measurement in GEN2.2 cells and primary pDCs

   PMID:29535732

   Open questions at the time

   • Transcriptional targets of c-FOS that repress IFN genes not defined
   • Single-lab pathway dissection
10. 2019 High

    Dissecting BST2 ectodomain subregions revealed that the coiled-coil provides the ILT7-binding surface and its conformational plasticity triggers signaling while the N-terminal region suppresses activation, establishing the structural logic of receptor engagement.

    Evidence Biophysical binding studies, BST2 domain mutagenesis, coiled-coil stability analysis, homodimer binding assessment, and two orthogonal ILT7 activation assays

    PMID:31118237

    Open questions at the time

    • No co-crystal or high-resolution structure of the BST2–ILT7 interface
    • Post-binding conformational mechanism not visualized at atomic resolution
11. 2024 Low

    Confirming Bst2-ILT7 interactions in a viral myocarditis model extended the axis beyond pDC homeostasis and HIV into tissue inflammation and therapeutic manipulation.

    Evidence Single-cell RNA sequencing of cardiac CD45+ cells, in vivo immunoglobin treatment, and coxsackievirus B3 mouse fulminant myocarditis model with ligand-receptor analysis

    PMID:39442535

    Open questions at the time

    • Mechanistic detail limited; based largely on inferred ligand-receptor interactions
    • Single model, single lab, causality not directly tested

• How ILT7 signaling intersects with pDC differentiation decisions and whether the BST2-ILT7 axis can be therapeutically tuned in human disease remain open.
• No atomic-resolution structure of the BST2–ILT7 complex
• Transcriptional output linking ERK-c-FOS to IFN gene repression undefined
• In vivo therapeutic relevance in humans untested